Jerel Davis and Marcelo Bigal (Versant)

'It's pure art': Ver­sant, GV re­veal $60M bet that a clear­er look at in­flam­ma­somes can lead to bet­ter drugs

For years, sci­en­tists had known about the myr­i­ad ways NL­RP3 push­es the in­nate im­mune sys­tem to go over­board and trig­ger au­toim­mune or in­flam­ma­to­ry dis­eases. But …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.